GENERAL
Glenmark Gets US FDA Approval For Fluticasone Propionate Nasal Spray
Glenmark Pharmaceuticals Ltd has received approval from the US Food and Drug Administration (US FDA) for Fluticasone Propionate Nasal Spray USP, 0.05 mg (50 mcg)/spray, strengthening its respiratory portfolio in the US market. The company said its Fluticasone Propionate Nasal Spray is bioequivalent and therapeutically equivalent to Flonase Nasal Spray, 0.05 mg/spray, the reference listed […]
CW Bureau
·
Aug 20, 2026
GENERAL
Glenmark Scales Up US Injectables Presence With Generic Sugammadex
Glenmark Pharmaceuticals Inc., USA, has launched Sugammadex Injection in the United States, expanding its injectables portfolio with a generic version of Merck Sharp & Dohme LLC’s blockbuster anaesthesia reversal drug BRIDION. The company said the product is available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials. Glenmark’s Sugammadex Injection […]
CW Bureau
·
Jul 29, 2026
GENERAL
Glenmark Specialty Advances Global Phase 3 Trial For Ovarian Cancer Drug
Glenmark Pharmaceuticals Ltd, through its wholly owned subsidiary Glenmark Specialty S.A., has advanced the Phase 3 clinical development of Trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate (ADC), for the treatment of platinum-resistant ovarian cancer (PROC). India will become the first country across Glenmark’s licensed markets to initiate patient enrolment for the global Phase 3 clinical trial […]
CW Bureau
·
Jul 2, 2026
GENERAL
Glenmark Pharma Launches Generic Vancomycin Injection In US Market
Glenmark Pharmaceuticals has announced the launch of Vancomycin Hydrochloride for Injection USP in the U.S. market, expanding its injectable portfolio amid growing demand for affordable hospital medicines. The company said the product will be available in 500 mg/vial and 1 g/vial strengths through its U.S.-based arm, Glenmark Pharmaceuticals Inc., USA. Targets $37.9 million market opportunity […]
CW Bureau
·
May 18, 2026
GENERAL
Glenmark Bolsters North America Portfolio With New Product Launch
Glenmark Pharmaceuticals has announced the upcoming launch of Sodium Phosphates Injection USP in multiple single-dose vial presentations, further strengthening its institutional product portfolio in the North American market. The company will introduce Sodium Phosphates Injection USP in 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) single-dose vials, […]
CW Bureau
·
Feb 27, 2026
